Dementia-Alzheimer’s Research Papers~ March 2000

Dementia-Alzheimer’s Research Papers~ March 2000 

           

Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol. 2000 Mar 30;393(1-3):141-6.

Bigl M, Beck M, Bleyl AD, Bigl V, Eschrich K. Altered phosphofructokinase mRNA levels but unchanged isoenzyme pattern in brains from patients with Alzheimer's disease. Brain Res Mol Brain Res. 2000 Mar 29;76(2):411-4.

Burghaus L, Schütz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schröder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res. 2000 Mar 29;76(2):385-8.

Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res. 2000 Mar 29;76(2):347-54.

Bi R, Broutman G, Foy MR, Thompson RF, Baudry M. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3602-7.

Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, Decarli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000 Mar 28;54(6):1316-23.

Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Two-dimensional structure of beta-amyloid(10-35) fibrils. Biochemistry. 2000 Mar 28;39(12):3491-9.

Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000 Mar 28;54(6):1265-72.

Cracowski JL, Stanke-Labesque F, Souvignet C, Bessard G. [Isoprostanes: new markers of oxidative stress in human diseases] Presse Med. 2000 Mar 25;29(11):604-10.

Chen Y, McPhie DL, Hirschberg J, Neve RL. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem. 2000 Mar 24;275(12):8929-35.

Liu J, Ho W, Lee NT, Carlier PR, Pang Y, Han Y. Bis(7)-tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats. Neurosci Lett. 2000 Mar 24;282(3):165-8.

Kimura T, Yamamoto H, Takamatsu J, Yuzuriha T, Miyamoto E, Miyakawa T. Phosphorylation of MARCKS in Alzheimer disease brains. Neuroreport. 2000 Mar 20;11(4):869-73.

Huang TH, Yang DS, Plaskos NP, Go S, Yip CM, Fraser PE, Chakrabartty A. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J Mol Biol. 2000 Mar 17;297(1):73-87.

Hauss-Wegrzyniak B, Vannucchi MG, Wenk GL. Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. Brain Res. 2000 Mar 17;859(1):157-66.

Song S, Ohba M, Saito Y, Honda T, Takashima A, Takahashi H. Proteolytic processing and degradation of human presenilin-1 expressed in yeast. Neurosci Lett. 2000 Mar 17;282(1-2):65-8.

Mattila KM, Axelman K, Rinne JO, Blomberg M, Lehtimäki T, Laippala P, Röyttä M, Viitanen M, Wahlund L, Winblad B, Lannfelt L. Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci Lett. 2000 Mar 17;282(1-2):45-8. ,

Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem. 2000 Mar 17;275(11):7918-24.

Mazurek AA. Treatment of Alzheimer's disease. N Engl J Med. 2000 Mar 16;342(11):821; discussion 821-2.

De Deyn PP. Treatment of Alzheimer's disease. N Engl J Med. 2000 Mar 16;342(11):821; discussion 821-2.

Fukui T, Kertesz A. Volumetric study of lobar atrophy in Pick complex and Alzheimer's disease. J Neurol Sci. 2000 Mar 15;174(2):111-21.

Marui W, Iseki E, Uéda K, Kosaka K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. J Neurol Sci. 2000 Mar 15;174(2):81-4.

Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol Psychiatry. 2000 Mar 15;47(6):557-61.

Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology. 2000 Mar 14;54(5):1109-16.

Verkkoniemi A, Somer M, Rinne JO, Myllykangas L, Crook R, Hardy J, Viitanen M, Kalimo H, Haltia M. Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology. 2000 Mar 14;54(5):1103-9.

McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000 Mar 14;54(5):1050-8.

  

Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2910-5. ,

Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000 Mar 14;39(10):2552-63.

  

Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2892-7. ,

Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T. Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney - possible role of transthyretin for abeta sequestration. Neurosci Lett. 2000 Mar 10;281(2-3):171-4.

Maldonado TA, Jones RE, Norris DO. Distribution of beta-amyloid and amyloid precursor protein in the brain of spawning (senescent) salmon: a natural, brain-aging model. Brain Res. 2000 Mar 10;858(2):237-51.

Blitzer RD, Wong T, Giovannini MG, Pangalos MN, Robakis NK, Landau EM. Amyloid beta peptides activate the phosphoinositide signaling pathway in oocytes expressing rat brain RNA. Brain Res Mol Brain Res. 2000 Mar 10;76(1):115-20.

  

Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000 Mar 10;275(10):7410-5.

 

Erwin JM. Alzheimer's research is vital in work on ageing. Nature. 2000 Mar 9;404(6774):120.

Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 2000 Mar 6;93(2):103-10.

Ikeda K, Iwasaki Y, Kinoshita M, Marubuchi S, Ono S. T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease. Brain Res. 2000 Mar 6;858(1):84-91.

Umegaki H, Ikari H, Nakahata H, Yoshimura J, Endo H, Yamamoto T, Iguchi A. Low plasma epinephrine in elderly female subjects of dementia of Alzheimer type. Brain Res. 2000 Mar 6;858(1):67-70.

McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT, Passmore AP. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet. 2000 Mar;37(3):182-5. ,

Sarangi S, San Pedro EC, Mountz JM. Anterior choroidal artery infarction presenting as a progressive cognitive deficit. Clin Nucl Med. 2000 Mar;25(3):187-90.

Pocernich CB, La Fontaine M, Butterfield DA. In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int. 2000 Mar;36(3):185-91.

Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int. 2000 Mar;36(3):175-84.

Pearce JM. Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):348.

Mathuranath PS, Xuereb JH, Bak T, Hodges JR. Corticobasal ganglionic degeneration and/or frontotemporal dementia? A report of two overlap cases and review of literature. J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):304-12.

Galton C. Clinical diagnosis and management of Alzheimer's disease, 2nd edition J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):398D.

Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol (Berl). 2000 Mar;99(3):296-304.

Ishihara Y, Goto G, Miyamoto M. Central selective acetylcholinesterase inhibitor with neurotrophic activity: structure-activity relationships of TAK-147 and related compounds. Curr Med Chem. 2000 Mar;7(3):341-54.

Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem. 2000 Mar;7(3):303-39.

Kaur J, Zhang MQ. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors. Curr Med Chem. 2000 Mar;7(3):273-94.

Baloyannis SJ, Manolidis SL, Manolidis LS. Synaptic alterations in the vestibulocerebellar system in Alzheimer's disease--a Golgi and electron microscope study. Acta Otolaryngol. 2000 Mar;120(2):247-50.

Melton L. Sex is all in the brain: report of a Novartis Foundation Symposium on the Neuronal and Cognitive Effects of Oestrogens, London, UK, 7-9 September 1999. Trends Endocrinol Metab. 2000 Mar;11(2):69-71.

Woo K. Is vitamin E the magic bullet for the treatment of Alzheimer's disease (AD)? Perspectives. 2000 Spring;24(1):7-10.

Scherder EJ. Low use of analgesics in Alzheimer's disease: possible mechanisms. Psychiatry. 2000 Spring;63(1):1-12.

 

  

Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000 Mar 1;20(5):1657-65.

 

Nunomura A, Chiba S. Avoidance of Apoptosis in Alzheimer's Disease. J Alzheimers Dis. 2000 Mar;2(1):59-60.

Velez-Pardo C, Lopera F, Jimenez Del Rio M. DNA Damage does not Correlate with Amyloid-beta-Plaques and Neurofibrillary Tangles in Familial Alzheimer's Disease Presenilin-1 [E280A] Mutation. J Alzheimers Dis. 2000 Mar;2(1):47-57.

Alafuzoff I, Overmyer M, Helisalmi S, Soininen H. Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. J Alzheimers Dis. 2000 Mar;2(1):37-46.

Andrási E, Farkas E, Gawlik D, Rösick U, Brätter P. Brain Iron and Zinc Contents of German Patients with Alzheimer Disease. J Alzheimers Dis. 2000 Mar;2(1):17-26.

Curran S, Wattis J. Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer's disease. Hum Psychopharmacol. 2000 Mar;15(2):103-112.

Melchor JP, Van Nostrand . Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. J Biol Chem. 2000 Mar;275(13):9782-91. Abstract

Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000 Mar-Apr;21(2):153-60.

Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging. 2000 Mar-Apr;21(2):245-55.

Postuma RB, He W, Nunan J, Beyreuther K, Masters CL, Barrow CJ, Small DH. Substrate-bound beta-amyloid peptides inhibit cell adhesion and neurite outgrowth in primary neuronal cultures. J Neurochem. 2000 Mar;74(3):1122-30.

Gélinas I, Gauthier S, Cyrus PA. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living. J Geriatr Psychiatry Neurol. 2000 Spring;13(1):9-16.

Knott V, Mohr E, Mahoney C, Ilivitsky V. Electroencephalographic coherence in Alzheimer's disease: comparisons with a control group and population norms. J Geriatr Psychiatry Neurol. 2000 Spring;13(1):1-8.

Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):357-61.

Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):349-55.

Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):343-8.

Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):321-30.

de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging. 2000 Mar-Apr;21(2):309-19.

Nagata K, Kondoh Y, Atchison R, Sato M, Satoh Y, Watahiki Y, Hirata Y, Yokoyama E. Vascular and metabolic reserve in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):301-7.

Lehtovirta M, Laakso MP, Frisoni GB, Soininen H. How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies. Neurobiol Aging. 2000 Mar-Apr;21(2):293-300.

Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging. 2000 Mar-Apr;21(2):289-92.

Solerte SB, Ceresini G, Ferrari E, Fioravanti M. Hemorheological changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer's type: adverse effects on cerebromicrovascular system. Neurobiol Aging. 2000 Mar-Apr;21(2):271-81.

Ajmani RS, Metter EJ, Jaykumar R, Ingram DK, Spangler EL, Abugo OO, Rifkind JM. Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol Aging. 2000 Mar-Apr;21(2):257-69. ,

Farkas E, de Vos RA, Jansen Steur EN, Luiten PG. Are Alzheimer's disease, hypertension, and cerebrocapillary damage related?. Neurobiol Aging. 2000 Mar-Apr;21(2):235-43.

Cada A, de la Torre JC, Gonzalez-Lima F. Chronic cerebrovascular ischemia in aged rats: effects on brain metabolic capacity and behavior. Neurobiol Aging. 2000 Mar-Apr;21(2):225-33.

Kudo T, Imaizumi K, Tanimukai H, Katayama T, Sato N, Nakamura Y, Tanaka T, Kashiwagi Y, Jinno Y, Tohyama M, Takeda M. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol Aging. 2000 Mar-Apr;21(2):215-24.

Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging. 2000 Mar-Apr;21(2):207-14.

Grammas P. A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):199-205.

Shadlen MF, Larson EB, Yukawa M. The epidemiology of Alzheimer's disease and vascular dementia in Japanese and African-American populations: the search for etiological clues. Neurobiol Aging. 2000 Mar-Apr;21(2):171-81.

Jansen-Dürr P, Wick G. EMBO workshop--"Molecular and Cellular Gerontology": Sepiano/Switzerland, September 18-22, 1999. Exp Gerontol. 2000 Mar;35(2):251-7.

Verma A. Alzheimer's: no pain or no complain? Psychiatry. 2000 Spring;63(1):13-5.

Knott V, Mohr E, Mahoney C, Ilivitsky V. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 2000 Mar;22(2):115-22.

Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol. 2000 Mar;22(2):89-95.

Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000 Mar;15(3):93-101.

Castellani RJ, Harris PL, Lecroisey A, Izadi-Pruneyre N, Wandersman C, Perry G, Smith MA. Evidence for a novel heme-binding protein, HasAh, in Alzheimer disease. Antioxid Redox Signal. 2000 Spring;2(1):137-42.

Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. Psychol Aging. 2000 Mar;15(1):18-28.

Chambers CB, Sigurdsson EM, Hejna MJ, Lorens SA, Lee JM, Muma NA. Amyloid-beta injection in rat amygdala alters tau protein but not mRNA expression. Exp Neurol. 2000 Mar;162(1):158-70.

Isobe I, Yanagisawa K, Michikawa M. A possible model of senile plaques using synthetic amyloid beta-protein and rat glial culture. Exp Neurol. 2000 Mar;162(1):51-60.

Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP, Miller SW, Davis RE, Parker WD. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol. 2000 Mar;162(1):37-50.

Papassotiropoulos A, Bagli M, Kurz A, Kornhuber J, Förstl H, Maier W, Pauls J, Lautenschlager N, Heun R. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann Neurol. 2000 Mar;47(3):399-403. ,

Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 2000 Mar 1;47(3):365-8. , ,

 

Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, Canal N, Griffin WS, Franceschi M. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000 Mar 1;47(3):361-5. , ,

 

Tanzi RE. Alzheimer's disease risk and the interleukin-1 genes. Ann Neurol. 2000 Mar;47(3):283-5.

 

Nitrini R, Buchpiguel CA, Caramelli P, Bahia VS, Mathias SC, Nascimento CM, Degenszajn J, Caixeta L. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurol Scand. 2000 Mar;101(3):172-6.

Claus JJ, Ongerboer de Visser BW, Bour LJ, Walstra GJ, Hijdra A, Verbeeten B, Van Royen EA, Kwa VI, van Gool WA. Determinants of quantitative spectral electroencephalography in early Alzheimer's disease: cognitive function, regional cerebral blood flow, and computed tomography. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):81-9.

Scott WK, Grubber JM, Conneally PM, Small GW, Hulette CM, Rosenberg CK, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet. 2000 Mar;66(3):922-32.

Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol. 2000 Mar;57(3):347-51.

Kaye JA. Methods for discerning disease-modifying effects in Alzheimer disease treatment trials. Arch Neurol. 2000 Mar;57(3):312-4.

McIlroy SP, Vahidassr MD, Savage DA, Lloyd F, Patterson CC, Lawson JT, Passmore AP. Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. Int J Geriatr Psychiatry. 2000 Mar;15(3):260-6. ,

Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000 Mar;15(3):242-7.

Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry. 2000 Mar;15(3):203-7.

Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol. 2000 Mar 1;156(3):951-64.

Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol. 2000 Mar;156(3):797-805. ,

Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000 Mar;7(2):159-69.

O'Brien JT, Metcalfe S, Swann A, Hobson J, Jobst K, Ballard C, McKeith I, Gholkar A. Medial temporal lobe width on CT scanning in Alzheimer's disease: comparison with vascular dementia, depression and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):114-8.

Hogervorst E, Barnetson L, Jobst KA, Nagy Z, Combrinck M, Smith AD. Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):107-13.

Thomas-Antérion C, Jacquin K, Laurent B. Differential mechanisms of impairment of remote memory in Alzheimer's and frontotemporal dementia. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):100-6.

Wehr H, Parnowski T, Puzynski S, Bednarska-Makaruk M, Bisko M, Kotapka-Minc S, Rodo M, Wolkowska M. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):70-3.

Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement Geriatr Cogn Disord. 2000 Mar-Apr;11(2):66-9.

Kuroda Y, Kawahara M. [Aluminum as a risk factor of Alzheimer's disease] No To Shinkei. 2000 Mar;52(3):222-9.

Kamino K, Ohta S. [Functional alteration of mitochondrial enzymes in Alzheimer's brain] No To Shinkei. 2000 Mar;52(3):193-200.

Schredl M, Weber B, Braus D, Gattaz WF, Berger M, Riemann D, Heuser I. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol. 2000 Mar;35(2):243-9.

Smith JD. Apolipoprotein E4: an allele associated with many diseases. Ann Med. 2000 Mar;32(2):118-27.

Roch-Arveiller M, Couderc R. [Caveolae membrane domains, specialized transmembrane exchange zones implicated in cell signalling] Ann Biol Clin (Paris). 2000 Mar-Apr;58(2):141-6.

  

Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 22-29;283(12):1571-7. ,

    

Rampa A, Bisi A, Belluti F, Gobbi S, Valenti P, Andrisano V, Cavrini V, Cavalli A, Recanatini M. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. Bioorg Med Chem. 2000 Mar;8(3):497-506.

Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, Dubois B. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial. J Am Geriatr Soc. 2000 Mar;48(3):268-74.

Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer's disease. Cereb Cortex. 2000 Mar;10(3):243-51.

Thulborn KR, Martin C, Voyvodic JT. Functional MR imaging using a visually guided saccade paradigm for comparing activation patterns in patients with probable Alzheimer's disease and in cognitively able elderly volunteers. AJNR Am J Neuroradiol. 2000 Mar;21(3):524-31.